Synthesis, Molecular Docking, and Bioactivity Study of Novel Hybrid Benzimidazole Urea Derivatives: A Promising α-Amylase and α-Glucosidase Inhibitor Candidate with Antioxidant Activity
Pharmaceutics · 30.01.2023 · 15 (2) · 457
DOI: 10.3390/pharmaceutics15020457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.01.2023. Verfasst von Lotfi M Aroua und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Science, Qassim University, Qassim Main Campus, King Abdulaziz Road, P.O. Box 6644, Al-Malida, Buraydah 51452, Sa…. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deputyship for Research& Innovation, Ministry of Education, Saudi Arabia, Deputyship for Research & Innovation, Ministry of Education, Saudi Arabia.
Abstract (Originalsprache)
A novel series of benzimidazole ureas 3a–h were elaborated using 2-(1H-benzoimidazol-2-yl) aniline 1 and the appropriate isocyanates 2a–h. The antioxidant and possible antidiabetic activities of the target benzimidazole-ureas 3a–h were evaluated. Almost all compounds 3a–h displayed strong to moderate antioxidant activities. When tested using the three antioxidant techniques, TAC, FRAP, and MCA, compounds 3b and 3c exhibited marked activity. The most active antioxidant compound in this family was compound 3g, which had excellent activity using four different methods: TAC, FRAP, DPPH-SA, and MCA. In vitro antidiabetic assays against α-amylase and α-glucosidase enzymes revealed that the majority of the compounds tested had good to moderate activity. The most favorable results were obtained with compounds 3c, 3e, and 3g, and analysis revealed that compounds 3c (IC50 = 18.65 ± 0.23 μM), 3e (IC50 = 20.7 ± 0.06 μM), and 3g (IC50 = 22.33 ± 0.12 μM) had good α-amylase inhibitory potential comparable to standard acarbose (IC50 = 14.21 ± 0.06 μM). Furthermore, the inhibitory effect of 3c (IC50 = 17.47 ± 0.03 μM), 3e (IC50 = 21.97 ± 0.19 μM), and 3g (IC50 = 23.01 ± 0.12 μM) on α-glucosidase was also comparable to acarbose (IC50 = 15.41 ± 0.32 μM). According to in silico molecular docking studies, compounds 3a–h had considerable affinity for the active sites of human lysosomal acid α-glucosidase (HLAG) and pancreatic α-amylase (HPA), indicating that the majority of the examined compounds had potential anti-hyperglycemic action.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, College of Science, Qassim University, Qassim Main Campus, King Abdulaziz Road, P.O. Box 6644, Al-Malida, Buraydah 51452, Saudi Arabia.
- Laboratory of Structural Organic Chemistry-Synthesis and Physicochemical Studies (LR99ES14), Department of Chemistry, Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis 2092, Tunisia.
- Faculty of Sciences of Bizerte, Carthage University, Jarzouna, Bizerte 7021, Tunisia.
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia.
- Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University, Cairo 11371, Egypt.
- Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Saveetha Nagar, Thandalam, Chennai 602105, India.
ORCID-Profile: Lotfi M Aroua, Fahad M Alminderej, Sabri Messaoudi, Hamdoon A Mohammed, Sridevi Chigurupati, Nejib H Mekni
Förderung
- Deputyship for Research& Innovation, Ministry of Education, Saudi Arabia
- Deputyship for Research & Innovation, Ministry of Education, Saudi Arabia
Zitieren
APA
Aroua, L. M., Alosaimi, A. H., Alminderej, F. M., Messaoudi, S., Mohammed, H. A., Almahmoud, S. A., Chigurupati, S., Albadri, A. E. A. E., & Mekni, N. H. (2023). Synthesis, Molecular Docking, and Bioactivity Study of Novel Hybrid Benzimidazole Urea Derivatives: A Promising α-Amylase and α-Glucosidase Inhibitor Candidate with Antioxidant Activity. Pharmaceutics, 15(2), 457. https://doi.org/10.3390/pharmaceutics15020457
Vancouver
Aroua LM, Alosaimi AH, Alminderej FM, Messaoudi S, Mohammed HA, Almahmoud SA, et al. Synthesis, Molecular Docking, and Bioactivity Study of Novel Hybrid Benzimidazole Urea Derivatives: A Promising α-Amylase and α-Glucosidase Inhibitor Candidate with Antioxidant Activity. Pharmaceutics. 2023;15(2):457. doi:10.3390/pharmaceutics15020457
BibTeX
@article{Aroua2023,
author = {Aroua, Lotfi M and Alosaimi, Abdulelah H and Alminderej, Fahad M and Messaoudi, Sabri and Mohammed, Hamdoon A and Almahmoud, Suliman A and Chigurupati, Sridevi and Albadri, Abuzar E A E and Mekni, Nejib H},
title = {Synthesis, Molecular Docking, and Bioactivity Study of Novel Hybrid Benzimidazole Urea Derivatives: A Promising α-Amylase and α-Glucosidase Inhibitor Candidate with Antioxidant Activity},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {2},
pages = {457},
doi = {10.3390/pharmaceutics15020457}
}
EUVIMED